红霉素与阿奇霉素治疗小儿支原体肺炎的最小成本分析

Cost-minimization Analysis on Erythromycin vs. Azithromycin in the Treatment of Mycoplasmal Pneumonia in Children

目的:探讨红霉素与阿奇霉素治疗小儿支原体肺炎的成本和效果。方法:运用药物经济学最小成本分析法对红霉素与阿奇霉素治疗小儿支原体肺炎方案进行回顾性分析。结果:两种治疗方案总有效率均为96.66%,差异无统计学意义(P>0.05);病原体清除率红霉素组为53.33%,阿奇霉素组为76.67%,差异有统计学意义(P<0.05);治疗成本,红霉素组为383.37元,阿奇霉素组为306.27元,差异有统计学意义(P<0.05)。结论:阿奇霉素与红霉素在治疗小儿支原体肺炎感染方面均有较好疗效,但前者疗效优于后者,具有成本少、清除支原体功能更强、缩短病程、不良反应少的特点,值得在儿童中推广应用。

OBJECTIVE： To evaluate the cost and effectiveness of erythromycin versus azithromycin in the treatment of mycoplasmal pneumonia in children. METHODS： The cost - minimization analysis in pharmacoeconornics was applied for retrospective evaluation of erythromycin vs. azithromycin in the treatment of children with mycoplasmal pneumonia. RESULTS ： The total effective rates of the two therapeutic regimes both were 96.66 %, showing no significant differences （ P 〉 0.05）; the bacterial clearance rate was 53.33% for the erythromycin group compared with 76.67% for the azithromycin group, showing significant differences between the two groups （ P 〈 0.05） ; the cost of treatment for erythromycin group was 383.37 yuan （RMB） versus 306.27 yuan （RMB） for azithromyein group, showing significant differences between the two groups （ P 〈 0.05 ）. CONCLUSION ： Both Azithromycin and Erythromycin are effective in the treatment of pulmonary infection in children with mycoplasmal pneumonia but Azithromycin is more effective, less expensive, more powerful in clearing mycoplasma than Erythromycin, and Azithromycin can also shorten patient＇s course of disease, thus its clinical use in Children deserves to be recommended in children.